# Pizarra — PT-pseudo_4c6b2b2bbf94 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_4c6b2b2bbf94
Task: 1

Encounter: Urology - outpatient on 16 Jan 2025.
Referrer: Dr. T. Hendriks (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 59-year-old male
  - PSA: 4.7 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.07 ng/mL²
  - PSA velocity: 1.47 ng/mL/yr
  - Prior PSA: 2.7 ng/mL
  - Prostate volume: 56.0 mL
  - Months since last PSA: 2
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.78553134 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Hypercholesterolaemia, Coronary artery disease
  - Problem list / PMHx: Hypertension, Hypercholesterolaemia, Coronary artery disease
  - Current medication: amlodipine, valsartan, lisinopril, metoprolol, simvastatin, rosuvastatin, aspirin 80 mg, atorvastatin
  - Allergies: NKA
  - Additional notes: PSA 4.7 ng/mL. PI-RADS 4. PSAD 0.07. Prostate volume 56 mL. csPCa 0.79.

Vitals: weight 75 kg, height 168 cm, BMI 26.6, BP 148/88 mmHg, HR 49 bpm. Smoking: Non-smoker.

Chief complaint: Assessment required due to prior biopsy results and a continuing upward trend in prostate-specific antigen levels.

History: A 59-year-old retired mechanical engineer, Mr. X, initially entered clinical investigation after a PSA elevation emerged in mid-2022. Marital: Never married. Lives alone; adult son nearby. His weekly routine includes light home weight-training twice weekly, complemented by a modest alcohol intake of seven units per week. He reports zero lower urinary tract symptoms on the IPSS scale, actively denying hematuria or pelvic discomfort. Smoking: Non-smoker. Cardiovascular comorbidities include Hypertension, Hypercholesterolaemia, Coronary artery disease. Active medication: amlodipine, valsartan, lisinopril, metoprolol, simvastatin, rosuvastatin, aspirin 80 mg, atorvastatin. His most recent cardiology assessment was conducted six months ago. He is concurrently undergoing conservative management for suspected obstructive sleep apnoea using positional therapy, and an Arabic interpreter has been arranged for his forthcoming consultation. prior biopsy bucket "Positive".

Physical examination: Normal DRE: The prostate gland presents as symmetrically enlarged with a smooth, rubbery consistency and no palpable nodules or asymmetry. General examination yields unremarkable findings, alongside a blood pressure of 148/88 mmHg and a resting heart rate of 49 bpm. Peripheral lymphadenopathy and abdominal masses are notably absent.

Patient info: retired mechanical engineer; Never married; Lives alone; adult son nearby.
Next of kin: Sibling (brother).

Lifestyle: alcohol 7 units / week; exercise Light weight-training at home, 2x/week; IPSS score: 0/35 (mild LUTS).

Recent other appointments: Sleep clinic — suspected obstructive sleep apnoea.
Admin: Interpreter (Arabic) requested for next visit.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.50 +/- 0.20   (95% CI 0.12-0.87)

Where the uncertainty comes from:
  - aleatoric  dA = 0.16  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.12  (few labelled cases resemble this one)
  - 6.4 effective neighbours out of 10; 3 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=4.0, bx_ord=3.0, psa=4.7, age=59.0, psad=0.07, dre_ord=0.0, vol=56.0, n_pmhx=3.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the visible panel variables (PI-RADS=4.0, PSA=4.7, PSA density=0.07, Age=59, DRE=Normal, Prostate Volume=56.0 mL, Prior Biopsy=Positive, csPCa probability=0.78553134) and could not weigh the clinical context, such as the specific interpretation of the prior positive biopsy result or the trajectory of the PSA velocity (1.47 ng/mL/yr).
The prior could not weigh the clinical significance of the prior positive biopsy result against the current PI-RADS 4 score, which is a high-risk finding, nor could it weigh the clinical context of the patient's cardiovascular comorbidities.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a wide uncertainty interval (0.50 +/- 0.20). This wide interval suggests the classifier is genuinely unable to distinguish between biopsy and no biopsy based on the limited input. The prior could be wrong because it failed to account for the guideline criterion that the decision hinges on retrieved documents like the MRI report and PSA trajectory, which are necessary to determine if the prior positive result warrants a repeat biopsy.

The suggestion could be wrong because the prior did not incorporate the guideline's emphasis on the MRI findings (PI-RADS 4) in conjunction with the prior biopsy status, which is a key factor the protocol expert noted is missing.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes - context regarding the prior positive biopsy
laboratory panel - full panel
family-history anamnesis - for risk stratification

GUIDELINE ANCHOR
The guideline states that the decision must come from retrieved documents: "whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed."

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_4c6b2b2bbf94", "radiology_report": "Subject: Multiparametric MRI of the Prostate\nFacility: LUMC (Leiden)\nDate: 10 Jan 2025\nClinical indication: Re-evaluation of prior prostate cancer diagnosis. Current PSA 4.7 ng/mL.\nFINDINGS: Glandular volume registers at 56.0 mL. T2 sequences highlight a discrete hypointense focus within the right peripheral zone at mid-gland level, spanning roughly 18 mm. Diffusion-weighted acquisition shows pronounced restriction, mirrored by hypointensity on the ADC map. Dynamic contrast studies capture early, localized enhancement contrasting with adjacent parenchyma. Seminal vesicles remain clear. Extracapsular extension and suspicious pelvic lymphadenopathy are conspicuously absent. Bladder and rectal contours are intact.\nIMPRESSION: PI-RADS 4 lesion in the right peripheral zone, mid-gland. Prostate volume 56.0 mL yielding a PSA density of 0.07 ng/mL/mL. csPCa predicted probability 0.78553134"}
get_psa_trend
{"case_id": "PT-pseudo_4c6b2b2bbf94", "psa_trend": [{"date": "Jun 2022", "val": 1.1}, {"date": "Sep 2023", "val": 4.6}, {"date": "Jan 2025", "val": 4.7}]}
get_previous_notes
{"case_id": "PT-pseudo_4c6b2b2bbf94", "previous_notes": [{"date": "22 Jan 2024", "author": "Dr. T. Hendriks (GP)", "text": "26 Jul 2023 - Dr. T. Hendriks (GP): Routine screening revealed a PSA level of 2.7 ng/mL. Subsequent testing verified the rise, prompting a discussion on lifestyle adjustments. The progressive trend necessitated a urology referral to commence diagnostic evaluation and obtain baseline imaging."}, {"date": "26 Jul 2023", "author": "Dr. T. Hendriks (GP)", "text": "22 Jan 2024 - Dr. T. Hendriks (GP): Consultation addressed the pending urology referral. The individual remains on his cardiovascular regimen with stable risk parameters while awaiting MRI slot allocation. A comprehensive clinical update has been transmitted to the urology team for review."}]}
get_lab_results
{"case_id": "PT-pseudo_4c6b2b2bbf94", "laboratory_results": [{"name": "PSA", "val": "4.7 ng/mL", "date": "30 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "0.54 ng/mL", "date": "30 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "12%", "date": "30 Dec 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "14.4 g/dL", "date": "30 Dec 2024", "flag": ""}, {"name": "WBC", "val": "4.9 x10^9/L", "date": "30 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "220 x10^9/L", "date": "30 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "96 umol/L", "date": "30 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "30 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "8.5 nmol/L", "date": "30 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "62 U/L", "date": "30 Dec 2024", "flag": ""}, {"name": "LDH", "val": "209 U/L", "date": "30 Dec 2024", "flag": ""}, {"name": "HbA1c", "val": "6.5 %", "date": "30 Dec 2024", "flag": ""}]}

NOT RETRIEVED
get_family_history
The family history of prostate cancer was not retrieved, which is not critical for the immediate decision based on the other retrieved data.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 4 lesion in the right peripheral zone, mid-gland, with diffusion restriction.
- PSA trend: Rising from 1.1 ng/mL (Jun 2022) to 4.7 ng/mL (Jan 2025), showing a significant upward trajectory.
- Previous notes: The patient was referred for diagnostic evaluation due to a progressive trend.

AGAINST sampling this patient now:
- Previous notes: Prior biopsy result was "Positive" (no grade documented).
- Lab results: Free PSA is 0.54 ng/mL (12%), which is borderline but not overtly high.

WHERE THIS LEANS
The evidence strongly suggests a need for further investigation due to the high-risk MRI finding (PI-RADS 4) and the clear upward PSA trajectory, which aligns with the guideline criterion that requires reviewing the lesion status against prior imaging.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

Although the patient has a prior positive biopsy, the decision to biopsy is warranted because the retrieved documents do not document the prior ISUP grade, which is necessary to select a definitive treatment pathway. The PI-RADS 4 finding in the right peripheral zone, combined with the significant PSA trajectory from 1.1 ng/mL to 4.7 ng/mL, suggests the need for tissue characterization. The evidence is borderline because the prior positive result lacks the necessary grading information to definitively rule out the need for re-sampling.

Variables that carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
